In the context of a trial studying intermittent preventive sulfadoxine-pyrimethamine treatment of malaria in infants in Lambaréné, Gabon, children aged 18-30 months were followed up after having received their last dose at an age of 15 months. In the intention-to-treat population, the protective efficacy against all malaria episodes was Ϫ18.0 (95% confidence interval, Ϫ97.4 to 29. 5; ). The protective efficacy against P p .529 first or only anemia episode was Ϫ45.3 (95% confidence interval, Ϫ234.5 to 36. 3; ). The protective efficacies were P p .375 negative and were not statistically significant. These results do not appear to support the concept of a rebound effect after intermittent preventive sulfadoxine-pyrimethamine treatment of malaria in infants.
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Intermittent preventive sulfadoxine-pyrimethamine treatment of malaria in infants (IPTi-SP) is a novel tool to control malaria [1] . In a series of clinical trials performed in recent years, this concept was tested across sub-Saharan Africa [2] . In Lambaréné, Gabon, 1189 infants received either SP (250 mg and 12.5 mg, respectively) or placebo at 3, 9, and 15 months of age in a randomized, placebo-controlled, double-blind trial. The drug was safe and well tolerated. At the end of the intervention period at month 18, the intervention was efficacious but did not reach statistical significance, with a reduction in risk of anemia of 22% (95% confidence interval [CI], Ϫ1% to 40%;
) and a reduction in risk of malaria of 17% (95% P p .06 CI, Ϫ24% to 45%;
) [3] . P p .36 IPTi aims to maximize the protective effects of malaria chemoprophylaxis while minimizing deleterious effects [1] . Continuous chemoprophylaxis has been shown to result in a rebound effect of malaria morbidity and/or mortality and/or an excess of malaria-related anemia after cessation of the intervention and is understood to be a result of a loss or delay in the acquisition of naturally acquired immunity attributable to a lack of exposure to parasites, independent from the drug used [1, [4] [5] [6] [7] . We report here on a 12-month follow-up period from 18 through 30 months of age, to assess for a possible rebound in morbidity after the cessation of IPTi-SP in the Lambaréné, Gabon study cohort.
Patients and methods. The study took place in Lambaréné, Gabon. The local malaria epidemiology, the study subjects, the trial methodology, and the results up to 18 months of age for this randomized, placebo-controlled, double-blind trial have been described in detail elsewhere [3] . The study was performed according to the International Conference on HarmonizationGood Clinical Practice guidelines and according to the amended Declaration of Helsinki. A trial-specific data and safety monitoring board independent of site and funding with a local safety monitor was constituted and was informed weekly about the study proceedings and possible adverse events. A safety panel convened by the IPTi Consortium collected and analyzed safety data from the individual study sites and their data and safety monitoring boards. The ethics committee of the International Foundation of the HAS approved the study. The trial was registered at clinicaltrials.gov (registration NCT00167843).
This study reported here covers a 12-month follow-up period encompassing months 18-30 of life of the study subjects, to assess a possible rebound effect of morbidity. Primary end points for rebound were (1) the proportion of children with at least 1 episode of anemia (defined as a hemoglobin level ! 8.0 g/dL) during months 18-30 of life and (2) the proportion of children with at least 1 episode of malaria (defined as pres- ence of any asexual Plasmodium falciparum parasitemia and either a rectal temperature of у38.5ЊC or a history of fever during the last 48 h reported by the mother) during months 18-30 of life. Field workers conducted monthly home visits for health status assessment. In cases of acute febrile disease, a finger-prick blood sample was obtained, and a thick blood film was examined. The active follow-up continued until 30 months of age. Analysis was based on a modified intention-to-treat population (ie, all infants that received at least 1 dose of IPTi). The according-to-protocol population included all subjects who had previously received all 3 drug administrations within the specified time limits. Time at risk started at 18 months and ended at 30 months of age. Children who were not actively seen for 6 consecutive months were not included in the according-toprotocol analysis. Rate ratios (episodes per person-year at risk) were calculated using negative binomial regression without covariates and was expressed as protective efficacy. The 3 weeks after malaria treatment were not included in the time at risk. Survival analysis was based on Kaplan-Meier curves and the log-rank test to compare time to first episode. Statistical analysis was performed using JMP5 (SAS Institute) and STATA (StataCorp) statistical software.
Results. Of 1189 study subjects (594 in the SP group and 595 in the placebo group) included in the study at birth, 602 (315 in the SP group and 287 in the placebo group) entered the follow-up phase at month 18 [3] . At month 30, 287 children in the SP group completed the 12-month follow-up period (28 children were lost to follow-up; 24 were lost to migration, 3 withdrew consent, and 1 died [death unrelated to study drug]), and 262 children in the placebo group completed the 12-month follow-up period (25 children were lost to follow-up because of migration). The loss to follow-up primarily attributable to migration observed here is in line with previously reported figures of the intervention phase. In the intention-to-treat analysis, protective efficacy against all malaria episodes was Ϫ18.0% (95% CI, Ϫ97.4 to 29.5;
). The protective efficacy P p .529 against the first or only anemia episode was Ϫ43.5% (95% CI, Ϫ265.3 to 43.7;
). Full results are given in Table 1 and P p .449 Figure 1 .
Discussion. In line with data published elsewhere [8] , our data confirm that IPTi-SP is not associated with a rebound effect of significance in an area of perennial malaria transmission and low insecticide-treated bed net coverage. Five trials with IPTi-SP have been reported so far apart from ours in Gabon [3] , 1 each from Tanzania [9, 10] and Mozambique [8] and 3 from Ghana [11] [12] [13] . One was performed in an area of highly seasonal transmission [11] , whereas all others were performed in areas of stable malaria transmission.
There was no significant rebound in the pooled analysis of all 6 trials looking at the 5-month period after the IPTi schedule was finished [2] . In the initial Tanzanian study, a 36% protective efficacy against malaria (parasitemia and fever) was sustained during the follow-up period from 10 through 24 months of age [10] . In the study in Mozambique, no rebound effect was reported during follow-up through the age of 24 months [8] . The IPTi trial in Navrongo [11] reported a 19% increase in malaria with high-density parasitemia (у5000 parasites/mL) 4-12 months after the last dose of IPTi (ie, during 16-24 months of age) but did not find any evidence of a rebound using other measures, including malaria (with a parasite density of !5000 parasites/mL), malaria hospitalizations, and anemia. In the Tamale and Kumasi trials [12, 13] in Ghana, a rebound in anemia was observed in the second year of life in subgroup analyses, but there was no rebound in other morbidity outcomes.
In the current study, we found negative protective efficacies that could be consistent with a rebound effect for malaria and anemia, although neither measure was statistically significant. This could be attributable to a lack of power because of the relatively low malaria incidence in our study population. However, a pooled analysis of data published elsewhere [2] did not find evidence that IPTi-SP is associated with a significant rebound effect. On the balance, we think that the present results are in line with those published in the other studies and do not support the concept of a rebound effect after the intervention.
